DALLAS, July 27, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring the specialty pharmaceutical company Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX) should be of particular interest to other pharmaceutical companies: GlaxoSmithKline plc. (NYSE:GSK), Sanofi-Aventis (NYSE:SNY), Sepracor Inc. (Nasdaq:SEPR), Life Technologies Corp. (Nasdaq:LIFE), King Pharmaceuticals (NYSE:KG) and Mylan Inc. (Nasdaq:MYL).
It is available at: http://www.beaconequity.com/i/SOMX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Somaxon Pharmaceuticals Inc. (SOMX) is a specialty pharmaceutical company focused on the research, development, marketing and commercializing proprietary drug therapies for the treatment of psychiatric and neurological disorders. The Company's lead drug candidate Silenor (doxepin) has completed four phase III clinical trials for the treatment of insomnia.
In the report, the analyst notes:
"Approximately 40 million people in the United States suffer from chronic sleep disorders, while 30 million more suffer from varying levels of severity of insomnia. In 2007, the results of the Sleep in America Poll revealed 65% of respondents reported having trouble sleeping a couple times per week.
"Silenor's active ingredient is doxepin, the most powerful pharmacological blockade agent of the H1 receptor, and taken in small dosages of 3 mg and 6 mg, is a good candidate for treating insomnia. Doxepin has shown in trials to function as an antagonist at 5-HT2a sites, suggesting the drug may promote sleep, as the receptor may be a primary location to affect deep, restful sleep. Doxepin's effect on the 5-HT2a site is unique, and may give the patent legs for successful commercialization of Silenor."
To read the entire report visit: http://www.beaconequity.com/i/SOMX
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.